Breast Cancer

Recent advancements in surgical techniques for breast cancer-related lymphedema offer promising results. A study comparing vascularized lymph node transfer and lymphaticovenous anastomosis finds significant improvements in lymphatic drainage, particularly beneficial in severe cases of breast cancer-related lymphedema.  Vascularized lymph node transfer (VLNT) and lymphaticovenous anastomosis (LVA) are microsurgical techniques that enhance lymphatic drainage in patients...

Proteasome inhibitors show distinct effects on microRNA regulation in breast cancer cell lines, a new study reveals. These findings emphasize the potential for microRNA-targeted approaches to refine treatment efficacy in breast cancer therapies. Breast cancer remains a substantial cause of cancer-related mortality among women worldwide. This cell culture study, published in Clinical and Translational Oncology,...

Increased risk for all-cause mortality seen with postpartum young-onset breast cancer in women with germline BRCA pathogenic variants Young-onset breast cancer (YOBC) with germline BRCA pathogenic variants (PVs) is associated with an increased risk for all-cause mortality if diagnosed within 10 years after childbirth, according to a study published online April 19 in JAMA Network Open. Zhenzhen Zhang,...

Salvianolic acid A, an anti-cancer agent, showed a potential effect on M2 tumor-associated macrophages in a cell culture study, which concluded that it may be useful for reprogramming these macrophages in the management of triple-negative breast cancer. Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with challenging management and a poor prognosis....

Findings seen among poor surgical candidates, with recurrence risk of 10 percent seen at 16 months Cryoablation can be performed effectively in nonsurgical breast cancer patients with varying tumors, according to a study presented at the annual meeting of the Society of Interventional Radiology, held from March 23 to 28 in Salt Lake City. Jolie...

In the IDEA trial, postmenopausal patients aged 50–69 years with pT1N0 unifocal invasive breast cancer who did not receive radiotherapy achieved a high level of disease control after 5 years. For over three decades, radiotherapy has been an essential part of the treatment following breast-conserving surgery (BCS) for patients with early-stage breast cancer. Recent studies...

Low-dose acetylsalicylic acid reduces inflammatory protein levels and tissue perfusion in dense breast tissue in postmenopausal women, according to the results of a new phase II clinical trial. High mammographic density is a major risk factor for breast cancer, contributing to approximately 30% of all breast cancer. There is a lack of research regarding the...

DRL-Trastuzumab was found to have similar efficacy, safety, pharmacokinetics, and immunogenicity as Herceptin in HER2-positive breast cancer patients in a randomized, double-blind study. Trastuzumab, marketed under the brand name Herceptin, is a standard therapy for human epidermal growth factor receptor 2 (HER2)-positive breast cancer. The drug DRL_TZ, a potential trastuzumab biosimilar to Herceptin, was developed...

The phase 2 DAISY trial confirms that T-DXd efficacy depends on HER2 expression in breast cancer cases. However, it shows that T-DXd also has moderate activity in HER2-non-expressing patients, suggesting an alternative mechanism of action. Breast cancer is among the five most common causes of cancer mortality. Despite improvements in its treatment, 5-year survival rates...